Opendata, web and dolomites

MD-SD-OCT

An innovative double technologies medical device for corneal diseases.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MD-SD-OCT" data sheet

The following table provides information about the project.

Coordinator
COSTRUZIONI STRUMENTI OFTALMICI C.S.O. SRL 

Organization address
address: VIA DEGLI STAGNACCI 12 E
city: BADIA A SETTIMO
postcode: 50018
website: www.csoitalia.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.csoitalia.it/it/pagina/10-rd
 Total cost 1˙965˙867 €
 EC max contribution 1˙965˙867 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COSTRUZIONI STRUMENTI OFTALMICI C.S.O. SRL IT (BADIA A SETTIMO) coordinator 1˙965˙867.00

Map

 Project objective

It has been observed that eye related disease such Keratoconus, glaucoma and cataract are recently increased, especially in older adult, which are commonly more prone to this kind of pathology, with a significant rise also in young adults subject, due to nowadays lifestyle. The first main objective of CSO business project is to introduce into the market the innovative MD-SD-OCT, a new ophthalmology instrument, which is able to detect, with a single tool, a range of optical pathologies wider than the state of the art technologies are capable to support, with higher performances and significant reduction of manufacturing cost. This target will be reached through the integration of traditional topography approach (Placido's disk) and innovative patented Spectral Domain Optical Coherence Tomography (ref. WO 2014/155286 A1), into a single, compact and flexible diagnosis device, real breakthrough for the market at the state of art. As a results of the technology innovation proposed and due to the usage of a less expensive technology invented by CSO (new SD-OCT management system, covered by international patent), the overall cost of the device is significantly lower than the existing applicable technology (about 45% less). This aspect will be the most disruptive and distinguishing element of the entire business project and will determine a huge increase of the company competitiveness. As a result of intensive market need research, performed by the company in the last two years, and thanks to its expertise in R&D for design and manufacturing of innovative ophthalmology diagnosis devices, CSO, with higher performance , significantly lower cost and new double technology MD-SD-OCT will be able to strongly improve its competitiveness in the market of ophthalmology diagnosis devices.

 Deliverables

List of deliverables.
Website release Demonstrators, pilots, prototypes 2019-07-24 14:45:54
Circulation of periodic press releases and publications of articles Demonstrators, pilots, prototypes 2019-07-24 14:45:54

Take a look to the deliverables list in detail:  detailed list of MD-SD-OCT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MD-SD-OCT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MD-SD-OCT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Read More